Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Safety and efficacy of temsirolimus in heavily pretreated patients with metastatic renal cell carcinoma.

Lamm W, Vogl UM, Bojic M, Zielinski C, Klingler C, Kramer G, Schmidinger M.

Acta Oncol. 2012 Jan;51(1):101-6. doi: 10.3109/0284186X.2011.589404. Epub 2011 Jul 8.

PMID:
21736504
2.

Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza H.

Jpn J Clin Oncol. 2012 Sep;42(9):836-44. doi: 10.1093/jjco/hys110. Epub 2012 Jul 26.

PMID:
22844126
3.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

4.

Temsirolimus for patients with metastatic renal cell carcinoma: outcomes in patients receiving temsirolimus within a compassionate use program in a tertiary referral center.

Afshar M, Pascoe J, Whitmarsh S, James N, Porfiri E.

Drug Des Devel Ther. 2014 Dec 17;9:13-9. doi: 10.2147/DDDT.S73686. eCollection 2015.

5.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

Motzer RJ, Hudes GR, Curti BD, McDermott DF, Escudier BJ, Negrier S, Duclos B, Moore L, O'Toole T, Boni JP, Dutcher JP.

J Clin Oncol. 2007 Sep 1;25(25):3958-64.

PMID:
17761980
6.

Temsirolimus in renal cell carcinoma.

Otto T, Eimer C, Gerullis H.

Transplant Proc. 2008 Dec;40(10 Suppl):S36-9. doi: 10.1016/j.transproceed.2008.10.006.

PMID:
19100905
7.

FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

Kwitkowski VE, Prowell TM, Ibrahim A, Farrell AT, Justice R, Mitchell SS, Sridhara R, Pazdur R.

Oncologist. 2010;15(4):428-35. doi: 10.1634/theoncologist.2009-0178. Epub 2010 Mar 23.

8.

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L.

J Clin Oncol. 2005 Aug 10;23(23):5314-22. Epub 2005 Jun 13.

PMID:
15955899
9.

A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.

Fujisaka Y, Yamada Y, Yamamoto N, Horiike A, Tamura T.

Jpn J Clin Oncol. 2010 Aug;40(8):732-8. doi: 10.1093/jjco/hyq047. Epub 2010 Apr 29.

PMID:
20430774
10.

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

Hudes GR, Berkenblit A, Feingold J, Atkins MB, Rini BI, Dutcher J.

Semin Oncol. 2009 Dec;36 Suppl 3:S26-36. doi: 10.1053/j.seminoncol.2009.10.013. Review.

PMID:
19963097
11.

Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma.

Malizzia LJ, Hsu A.

Clin J Oncol Nurs. 2008 Aug;12(4):639-46. doi: 10.1188/08.CJON.639-646. Review.

PMID:
18676330
12.

Temsirolimus in daily use: results of a prospective multicentre noninterventional study of patients with metastatic kidney cancer.

Schrader AJ, Seseke S, Keil C, Herrmann E, Goebell PJ, Weikert S, Steffens S, Bergmann L, Roigas J, Steiner T.

Eur Urol. 2014 Aug;66(2):275-81. doi: 10.1016/j.eururo.2013.08.055. Epub 2013 Aug 31.

PMID:
24012472
13.

Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus.

Lee CK, Marschner IC, Simes RJ, Voysey M, Egleston B, Hudes G, de Souza P.

Clin Cancer Res. 2012 Jun 1;18(11):3188-96. doi: 10.1158/1078-0432.CCR-11-3137. Epub 2012 Apr 3.

14.

An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.

Grünwald V, Karakiewicz PI, Bavbek SE, Miller K, Machiels JP, Lee SH, Larkin J, Bono P, Rha SY, Castellano D, Blank CU, Knox JJ, Hawkins R, Anak O, Rosamilia M, Booth J, Pirotta N, Bodrogi I; REACT Study Group.

Eur J Cancer. 2012 Feb;48(3):324-32. doi: 10.1016/j.ejca.2011.06.054. Epub 2011 Jul 29.

PMID:
21803569
15.

Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study.

Merchan JR, Qin R, Pitot H, Picus J, Liu G, Fitch T, Maples WJ, Flynn PJ, Fruth BF, Erlichman C.

Cancer Chemother Pharmacol. 2015 Mar;75(3):485-93. doi: 10.1007/s00280-014-2668-5. Epub 2015 Jan 3.

16.

Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer.

Paterson C, Jones RJ.

Clin Oncol (R Coll Radiol). 2009 Nov;21(9):732-3. doi: 10.1016/j.clon.2009.07.006. Epub 2009 Aug 7. No abstract available.

PMID:
19665360
17.

Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.

Mancuso A, Di Paola ED, Leone A, Catalano A, Calabrò F, Cerbone L, Zivi A, Messina C, Alonso S, Vigna L, Caristo R, Sternberg CN.

BJU Int. 2012 Jan;109(2):200-6. doi: 10.1111/j.1464-410X.2011.10421.x.

18.

Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.

Calvo E, Escudier B, Motzer RJ, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Ravaud A, Kim D, Panneerselvam A, Anak O, Figlin RA.

Eur J Cancer. 2012 Feb;48(3):333-9. doi: 10.1016/j.ejca.2011.11.027. Epub 2011 Dec 30.

PMID:
22209391
19.

Experiences and practical conclusions concerning temsirolimus use and adverse event management in advanced renal cell carcinoma within a compassionate use program in Germany.

Gerullis H, Bergmann L, Maute L, Eimer C, Otto T.

Cancer Chemother Pharmacol. 2009 May;63(6):1097-102. doi: 10.1007/s00280-008-0835-2. Epub 2008 Sep 26.

PMID:
18818922
20.

Rechallenge with mTOR inhibitors in metastatic renal cell carcinoma patients who progressed on previous mTOR inhibitor therapy.

Maj-Hes A, Medioni J, Scotte F, Schmidinger M, Kramer G, Combe P, Gornadha Y, Elaidi R, Oudard S.

Oncology. 2013;85(1):8-13. doi: 10.1159/000350005. Epub 2013 Jun 21.

PMID:
23797151

Supplemental Content

Support Center